

Michigan MEDICATION SECTION DILTIAZEM

Initial Date: 07/19/2023

Revised Date: 08/11/2023

Section: 9-21R

Diltiazem

Pharmacological Category: Antiarrhythmic Agent, Calcium Channel Blocker

Routes: IV/IO

Indications:

 Symptomatic Tachycardia: Narrow Complex (Regular and Narrow or Irregular and Narrow rhythms)

Contraindications:

- 1. Patients with diagnosed sinus node dysfunction (e.g., sick sinus syndrome, WPW syndrome) unless pacemaker is present and functioning.
- 2. Patients with diagnosed or observed high-grade AV block (i.e., 2nd or 3rd degree heart block) unless pacemaker is present and functioning.

Precautions:

1. Be prepared to administer fluid bolus

Expected effects:

1. Resolution of rapid ventricular response or return to NSR

Side effects:

1. Hypotension

Dosing: ADULT TACHYCARDIA

Indication: Regular Narrow Complex Tachycardia (i.e., SVT, A-Flutter) and Irregular Narrow Complex Tachycardia (i.e., A-Fib/A-Flutter)

Adults administer:

1. Diltiazem 15-20 mg (0.25 mg/kg) IV slowly

Used in the Following Protocols

Tachycardia (Section 5 – Adult Cardiac)

MCA Name: HEMS, Inc. (WW/DR) MCA Board Approval Date: 2/8/2024 MCA Implementation Date: 3/1/2024

MDHHS Approval: 8/11/23 M

Page 1 of 1